<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157270</url>
  </required_header>
  <id_info>
    <org_study_id>CLP 14788</org_study_id>
    <nct_id>NCT04157270</nct_id>
  </id_info>
  <brief_title>LOTUS: Global Acute Stroke Study Utilizing Penumbra System</brief_title>
  <acronym>LOTUS</acronym>
  <official_title>LOTUS: Global Acute Stroke Study Utilizing Penumbra System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate safety and effectiveness of the
      Penumbra System in a population with acute ischemic stroke (AIS) secondary to intracranial
      large vessel occlusion (LVO).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>mTICI Score</measure>
    <time_frame>Immediate Post Procedure</time_frame>
    <description>Angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by a modified treatment in cerebral infarction (mTICI) score of 2b or higher. mTICI scale ranges from 0 to 3 with higher values representing better outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Subject Outcome</measure>
    <time_frame>90 days post</time_frame>
    <description>Good functional subject outcome at 90 days post-procedure as defined by modified Rankin Scale (mRS) 0-2. mRS scale from from 0 to 6 with higher values representing a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality at 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>All-cause mortality at 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Device and procedure related SAE</measure>
    <time_frame>Up to 30 days Post Procedure</time_frame>
    <description>Incidence of device and procedure related Serious Adverse Events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Occurrence of ENT</measure>
    <time_frame>Immediate Post Procedure</time_frame>
    <description>Occurrence of embolization in previously uninvolved (or new) territories (ENT) as seen on the final control angiogram at the end of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Occurrence of Symptomatic intracranial hemorrhage</measure>
    <time_frame>Up to 24 Hours Post Procedure</time_frame>
    <description>Occurrence of symptomatic hemorrhages (sICH) at 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Time</measure>
    <time_frame>Immediate Post Procedure</time_frame>
    <description>Time from the arterial puncture to revascularization defined by mTICI 2b or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Onset to Revascularization</measure>
    <time_frame>Immediate Post Procedure</time_frame>
    <description>Time from stroke onset to revascularization defined by mTICI 2b or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Revascularization</measure>
    <time_frame>Immediate Post Procedure</time_frame>
    <description>Complete revascularization, defined as mTICI 2c and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of index hospital stay</measure>
    <time_frame>Up to 90 days Post Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Discharge Facility</measure>
    <time_frame>Up to 90 days Post Procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>Patients with acute ischemic stroke</arm_group_label>
    <description>Patients with acute ischemic stroke secondary to intracranial large vessel occlusion (LVO)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Penumbra System</intervention_name>
    <description>Penumbra System</description>
    <arm_group_label>Patients with acute ischemic stroke</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients experiencing acute ischemic stroke secondary to intracranial large vessel
        occlusion who are eligible for mechanical thrombectomy using the Penumbra System
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age ≥ 18 and ≤ 85

          -  Patient experiencing acute ischemic stroke secondary to intracranial large vessel
             occlusion who are eligible for mechanical thrombectomy using the Penumbra System

          -  Planned frontline treatment with aspiration utilizing Penumbra System

          -  Present with symptoms consistent with an acute ischemic stroke within 8 hours of
             stroke symptom onset

          -  National Institute of Health Stroke Scale (NIHSS) ≥ 6

          -  Signed informed consent per Institution Review Board/Ethics Committee

          -  CT ASPECT score from 6 to 10 (≥ 6) or according to MR DWI ASPECT score from 5 to 10 (≥
             5)

          -  Pre-stroke mRS 0-1

        Exclusion Criteria:

          -  Any comorbid disease or condition expected to compromise survival or ability to
             complete follow-up assessments through 90 days

          -  Associated myocardial infarction or severe infection (endocarditis or sepsis)

          -  Laboratory evidence of coagulation abnormalities, with an International Normalized
             Ratio (INR) or &gt; 3.0 or platelets count &lt; 40 x 10^9/L or PTT/APTT &gt; 50 sec

          -  Uncontrolled hypertension (defined as systolic blood pressure &gt; 185 mmHg or diastolic
             blood pressure &gt; 110 mmHg)

          -  Baseline glucose &lt; 2.7 or &gt; 22.2 mmol/L

          -  Seizure at the onset of stroke

          -  Time of stroke symptom onset unknown

          -  Females who are pregnant

          -  Known serious sensitivity to radiographic contrast media that cannot be pre-treated

          -  Renal failure as defined by serum creatinine &gt; 3.0mg/dl (264 µmol/L)

          -  Currently participating in an investigational (drug, device, etc.) clinical trial that
             will confound study endpoints. Patients in observational, natural history, and/or
             epidemiological studies not involving intervention are eligible

          -  CT/MRI evidence of the following conditions at screening: significant mass effect with
             midline shift, evidence of intracranial hemorrhage (ICH), aneurysm, or arteriovenous
             malformation (AVM), or intracranial tumor

          -  . Angiographic evidence of preexisting arterial injury, such as carotid dissection,
             complete cervical carotid occlusion, or vasculitis.

          -  Angiographic evidence of occlusions in multiple vascular territories (e.g., bilateral
             anterior circulation, or anterior circulation/vertebrobasilar system) as confirmed on
             CTA/MRA, or clinical evidence of bilateral strokes or strokes in multiple territories

          -  Excessive arterial tortuosity that would prevent the device from reaching the target
             vessel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amaelle Schortgen</last_name>
    <phone>+33 6 34 30 21 12</phone>
    <email>aschortgen@penumbrainc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michaella Corso</last_name>
    <phone>+1 510-995-2079</phone>
    <email>mcorso@penumbrainc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RIA</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Frei, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital/USF</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeguang Ren, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Large Vessel Occlusion</keyword>
  <keyword>LVO</keyword>
  <keyword>Mechanical Thrombectomy</keyword>
  <keyword>Penumbra System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

